Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
暂无分享,去创建一个
R. Collins | A. Farmer | R. Peto | A. Neil | C. Baigent | S. Parish | A. Adler | J. Armitage | M. Mafham | R. Haynes | L. Bowman | F. Chen | K. Wallendszus | W. Stevens | E. Sammons | G. Buck | J. Barton | K. Murphy | T. Aung | J. Cox | A. Murawska | A. Young | M. Lay | E. Waters | J. Bodansky | R. Mcpherson | D. Simpson | A. Adler | Fang Chen | Theingi Aung | Emma Waters
[1] R. Collins,et al. Effects of n‐3 Fatty Acid Supplements in Diabetes Mellitus , 2018, The New England journal of medicine.
[2] N. Cook,et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials , 2018, The Lancet.
[3] R. Hunt,et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials , 2018, The lancet. Gastroenterology & hepatology.
[4] R. Collins,et al. ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes , 2017, American heart journal.
[5] Deepak L. Bhatt,et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.
[6] Deepak L. Bhatt,et al. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. , 2017, The Canadian journal of cardiology.
[7] J. Armitage,et al. Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND) , 2016, Trials.
[8] E. V. van Dijk,et al. Cognitive Impairment in Transient Ischemic Attack Patients: A Systematic Review , 2016, Cerebrovascular Diseases.
[9] K. Shimada,et al. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Japanese Patients 60 Years of Older With Atherosclerotic Risk-Factors: A Randomized Clinical Trial , 2015 .
[10] P. Rothwell,et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials , 2012, The Lancet.
[11] Gianni Tognoni,et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials , 2012, The Lancet.
[12] John Spertus,et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. , 2011, Circulation.
[13] P. Rothwell,et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials , 2011, The Lancet.
[14] G. Moneta. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2011 .
[15] A. Algra,et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.
[16] P. Sandercock,et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. , 2010, JAMA.
[17] R. Collins,et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.
[18] T. Morimoto,et al. Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes , 2012 .
[19] P. Macfarlane,et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease , 2008, BMJ : British Medical Journal.
[20] R. Storey,et al. Aspirin resistance and diabetes mellitus , 2008, Diabetologia.
[21] P. Rothwell,et al. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies , 2007, The Lancet.
[22] R. Peto,et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.
[23] P. Armitage,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.